Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

Rhea-AI Summary

Cortexyme, Inc. (NASDAQ: CRTX) announced its participation in H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. CEO Casey Lynch and COO Chris Lowe will discuss advancements in their pivotal GAIN trial for Alzheimer’s, with top-line data expected by mid-November 2021. The company is focused on developing therapeutics for degenerative diseases, including Alzheimer's and Parkinson's, targeting the infectious pathogen P. gingivalis. A webcast of the event will be available on Cortexyme's investor website, archived for 90 days.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Casey Lynch, chief executive officer, co-founder, and chair, and Chris Lowe, chief operating officer and chief financial officer, will participate in a fireside chat at H.C. Wainwright 23^rd Annual Global Investment Conference taking place virtually on Monday, September 13, 2021 at 7:00 a.m. Eastern Time.

A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer's disease with top-line data expected by mid-November 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson’s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005282/en/

Corporate Contact:

Stacy Roughan

Vice President, Corporate Communications & Investor Relations

Cortexyme, Inc.

ir@cortexyme.com

Source: Cortexyme, Inc.

FAQ

What is Cortexyme's role in the fight against Alzheimer's disease?

Cortexyme is advancing a pivotal trial called the GAIN trial for mild to moderate Alzheimer's disease, with top-line data expected by mid-November 2021.

When is Cortexyme participating in the H.C. Wainwright conference?

Cortexyme will participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. Eastern Time.

What is Cortexyme's primary focus in its drug development?

Cortexyme focuses on developing therapeutics for degenerative diseases, particularly targeting the pathogen P. gingivalis associated with Alzheimer's and other conditions.

Where can I find the webcast for Cortexyme's conference participation?

The webcast for Cortexyme's participation in the conference can be accessed via their Investor Calendar on the investor website and will be archived for 90 days.

What other diseases is Cortexyme targeting besides Alzheimer's?

Cortexyme is also developing therapeutics for Parkinson's disease, periodontitis, and other diseases with high unmet clinical need.